The world of biotech business often mimics the rough-and-tumble world of the animal kingdom—companies preen for investors as if searching for mates, for example, and the fierce competition in each sphere is well documented. Now, a recent trend toward reverse mergers—whereby a product or technology-rich firm reaches the public markets through the acquisition of a down-on-its-luck but comparably cash-rich public company—adds another parallel.
In the recent popular documentary the March of the Penguins, we learn that the female emperor penguins that have recently...





